FDA grants accelerated approval to neladalkib (Nelkarmi) for previously treated ALK-positive NSCLC, with confirmed response rates of 49% and 32%.
Written By: Siddhi Bhadekar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
U.S. Food and Drug Administration (FDA) granted accelerated approval to neladalkib (Nelkarmi) on November 17, 2026, for adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have been previously treated with ALK-directed therapies. Developed by Nuvalent, the oral kinase inhibitor addresses significant therapeutic resistance following progression on existing ALK tyrosine kinase inhibitors (TKIs).
Regulatory Basis of the Accelerated Approval
The application received FDA priority review, while neladalkib previously received breakthrough therapy and orphan drug designations. The FDA also used the Assessment Aid, a voluntary submission prepared by the applicant to support its regulatory review.
The accelerated approval was based on confirmed overall response rate (ORR) and duration of response (DOR) from the single-arm ALKOVE-1 study rather than a randomized comparison. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial.
FDA-Defined Indication and Dosing
Nelkarmi is approved for adults with unresectable locally advanced or metastatic ALK-positive NSCLC previously treated in the same disease setting with either:
- One prior ALK TKI consisting of alectinib.
- Two or more prior ALK TKIs and platinum-based chemotherapy.
The recommended dose is 150 mg orally once daily, with or without food, at approximately the same time each day until disease progression or unacceptable toxicity.
Clinical Evidence from ALKOVE-1
The approval was supported by ALKOVE-1 (NCT05384626) a global, multicenter, single-arm, open-label Phase I/II trial evaluating neladalkib in patients with advanced ALK-positive NSCLC and other ALK-positive solid tumours. The regulatory efficacy analysis included 222 patients across two cohorts: 67 previously treated with alectinib as their only prior ALK TKI and 155 who had received two or more prior ALK TKIs and platinum-based chemotherapy.
The major efficacy endpoints were confirmed ORR and DOR according to RECIST v1.1, assessed by blinded independent central review (BICR).
Treatment history | Confirmed ORR (95% CI) | DOR ≥6 months* | DOR ≥12 months* |
One prior ALK TKI (alectinib), n=67 | 49% (33/67; 37–62) | 76% | 52% |
≥2 prior ALK TKIs plus chemotherapy, n=155 | 32% (50/155; 24–40) | 69% | 51% |
*Proportion of responding patients.
The alectinib-only cohort demonstrated a higher ORR, while response durability at 12 months was comparable across both populations. These findings should be interpreted descriptively because the cohorts were not designed for head-to-head comparison.
Intracranial Activity in Patients with CNS Metastases
Additional results reported by GSK showed intracranial activity among patients with measurable central nervous system (CNS) metastases at baseline. Intracranial ORR was 55% (11/20), including 25% complete responses, in the alectinib-only cohort. In the multiple-TKI and chemotherapy cohort, intracranial ORR was 26% (14/53), including 11% complete responses.
These findings provide additional evidence of antitumour activity in patients with CNS involvement, an important consideration in ALK-positive NSCLC.
Safety Findings and Prescribing Information Warnings
The prescribing information includes warnings and precautions for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase (CPK) elevation and embryo-fetal toxicity.
The most common adverse reactions (≥20%) were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue. In the pooled safety population of 700 patients, hepatotoxicity occurred in 56%, including Grade 3 events in 18% and Grade 4 events in 7%.
Permanent treatment discontinuation due to adverse reactions occurred in 5% of patients, with hepatotoxicity being the most frequent reason for discontinuation. The prescribing information recommends regular liver function monitoring during treatment.
ALK-Positive NSCLC: Treatment Context and Clinical Interpretation
ALK rearrangements define a molecular subset of NSCLC commonly managed with targeted ALK inhibitors. However, resistance and disease progression following successive targeted therapies can complicate treatment selection, eventually requiring alternative treatment approaches, including chemotherapy.
ALKOVE-1 demonstrated confirmed and durable responses to neladalkib in two previously treated populations, including patients who had received multiple ALK TKIs and platinum-based chemotherapy. The intracranial response findings further indicate activity in patients with measurable CNS metastases.
However, the single-arm design limits comparative interpretation, and the FDA announcement does not report progression-free or overall survival outcomes. Confirmatory evidence will be important to establish clinical benefit and further define neladalkib’s position in the ALK-positive NSCLC treatment sequence.
Reference
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer, US FDA, 17 November 2026
A Study of Neladalkib (NVL-655) in Patients with Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1), ClinicalTrials.gov ID NCT05384626
Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer, GSK, 17 November 2026
About the Writer
Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.
